ArticleArchives of gynecology and obstetrics2017
Endometrial cancer arising in adenomyosis versus endometrial cancer coexisting with adenomyosis: are these two different entities?
Article in Archives of gynecology and obstetrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Impact of adenomyosis on the prognosis of patients with endometrial cancer.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2022Pooled it
- Adenomyosis as a Risk Factor for Myometrial or Endometrial Neoplasms-Review.International journal of environmental research and public health · 2022Pooled it
- Prevalence of adenomyosis in endometrial cancer patients: a systematic review and meta-analysis.Archives of gynecology and obstetrics · 2021Pooled it
- Multi-institutional study of mesonephric-like adenocarcinoma: its clinicopathological characteristics and histogenetic association with ectopic endometrium.Virchows Archiv : an international journal of pathology · 2026Article
- Review
- Coexistence of gynecological pathology with endometriosis and adenomyosis.Molecular and clinical oncology · 2026Article
- Prognostic impact of adenomyosis in cervical cancer: insights from machine learning-driven survival analysis.Revista da Associacao Medica Brasileira (1992) · 2026Article
- Impact of uterine adenomyosis on survival outcome of patients with non-endometrioid endometrial cancer.BMC cancer · 2025Article
- Adenomyosis as a prognostic factor in ovarian cancer: a retrospective study.Archives of gynecology and obstetrics · 2025Article
- Adenomyosis and endometrial cancer: determining its role as a biological contributor or incidental coexistence.BMC cancer · 2025Article
- A rare case of concomitant endometrioid adenocarcinoma arising from uterine adenomyosis and clear cell carcinoma arising from parametrial deep endometriosis.BMC women's health · 2024Article
- Occult clear cell carcinoma arising from oxidative stress‑exposed cystic adenomyosis: A case report.Molecular and clinical oncology · 2024Article
- Clinical Characteristics and Local Histopathological Modulators of Endometriosis and Its Progression.International journal of molecular sciences · 2024Article
- Endometrial cancer arising from adenomyosis with unusual manifestation: A case report.Clinical case reports · 2024Article
- Clinics in diagnostic imaging (217).Singapore medical journal · 2023Article
- Adenomyosis and Its Possible Malignancy: A Review of the Literature.Diagnostics (Basel, Switzerland) · 2023Review
- Endometrioid adenocarcinoma arising in adenomyosis in a patient with pelvic organ prolapse-case report.BMC women's health · 2023Article
- Review
- Mucinous carcinoma originating from uterine adenomyosis: a case report.Journal of medical case reports · 2023Article
- Effect of adenomyosis on prognosis of patients with endometrial cancer.Revista da Associacao Medica Brasileira (1992) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeWhile adenomyosis is one of the most common benign histologic findings in hysterectomy specimens of endometrial cancer, demographics of endometrial cancer arising in adenomyosis (EC-AIA) has not been well elucidated. The aim of this study is to evaluate histopathological findings and disease-free survival (DFS) of EC-AIA in comparison to endometrial cancer coexisting with adenomyosis (EC-A).
methodsEC-AIA cases were identified via a systematic literature search (n = 46). EC-A cases were identified from a historical cohort that underwent hysterectomy-based surgical staging in two institutions (n = 350). Statistical comparisons of the two groups were based on univariate and multivariate analyses.
resultsThe EC-AIA group was significantly older than the EC-A group (58.9 versus 53.8, p = 0.002). As to tumor characteristics, 63.6% of EC-AIA cases reported tumor within the myometrium without endometrial extension. The EC-AIA group was significantly associated with more non-endometrioid histology (23.9 versus 14.8%; p = 0.002) and deep myometrial tumor invasion (51.6 versus 19.4%; p < 0.001) than EC-A. Tumor grade, stage, and nodal metastasis risk were similar (all, p > 0.05). In a univariate analysis, the EC-AIA group had a significantly decreased DFS compared to EC-A (5-year rates, 72.2 versus 85.5%, p = 0.001). After controlling for age, histology, tumor grade, and stage, EC-AIA remained an independent prognostic factor associated with decreased DFS compared to EC-A (adjusted-hazard ratio 2.87, 95% confidence interval 1.44-5.70, p = 0.031).
conclusionOur study demonstrated that EC-AIA has distinct tumor characteristics and a poorer survival outcome compared to EC-A. This suggests a benefit of recognition of this unique entity as an aggressive variant of endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.